(Q39873607)

English

The proteasome inhibitor bortezomib interacts synergistically with the histone deacetylase inhibitor suberoylanilide hydroxamic acid to induce T-leukemia/lymphoma cells apoptosis

scientific article published on 12 March 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

15 September 2017

The proteasome inhibitor bortezomib interacts synergistically with the histone deacetylase inhibitor suberoylanilide hydroxamic acid to induce T-leukemia/lymphoma cells apoptosis (English)

1 reference

Europe PubMed Central

15 September 2017

1 reference

based on heuristic

inferred from title

author name string

Q-L Zhang

1

1 reference

Europe PubMed Central

15 September 2017

L Wang

2

1 reference

Europe PubMed Central

15 September 2017

Y-W Zhang

3

1 reference

Europe PubMed Central

15 September 2017

X-X Jiang

4

1 reference

Europe PubMed Central

15 September 2017

F Yang

5

1 reference

Europe PubMed Central

15 September 2017

W-L Wu

6

1 reference

Europe PubMed Central

15 September 2017

A Janin

7

1 reference

Europe PubMed Central

15 September 2017

Z Chen

8

1 reference

Europe PubMed Central

15 September 2017

Z-X Shen

9

1 reference

Europe PubMed Central

15 September 2017

S-J Chen

10

1 reference

Europe PubMed Central

15 September 2017

W-L Zhao

11

1 reference

Europe PubMed Central

15 September 2017

publication date

12 March 2009

1 reference

Europe PubMed Central

15 September 2017

1 reference

Europe PubMed Central

15 September 2017

23

1 reference

Europe PubMed Central

15 September 2017

8

1 reference

Europe PubMed Central

15 September 2017

1507-1514

1 reference

Europe PubMed Central

15 September 2017

https://scigraph.springernature.com/pub.10.1038/leu.2009.41

0 references

Targeting the NF-kappaB signaling pathway in Notch1-induced T-cell leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.41

21 January 2018

Differential expression of NF-κB pathway genes among peripheral T-cell lymphomas

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.41

21 January 2018

Interleukin-7 in T-cell acute lymphoblastic leukemia: an extrinsic factor supporting leukemogenesis?

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.41

21 January 2018

Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.41

21 January 2018

Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.41

21 January 2018

Leukotriene B4 receptor inhibitor LY293111 induces cell cycle arrest and apoptosis in human anaplastic large-cell lymphoma cells via JNK phosphorylation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.41

21 January 2018

p38-MAP kinase activation followed by BIM induction is essential for glucocorticoid-induced apoptosis in lymphoblastic leukemia cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.41

21 January 2018

Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.41

21 January 2018

Histone deacetylases and cancer: causes and therapies

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.41

21 January 2018

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.41

21 January 2018

Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.41

21 January 2018

Interactions between bortezomib and romidepsin and belinostat in chronic lymphocytic leukemia cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.41

21 January 2018

In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.41

21 January 2018

Prognostic significance of bcl-xL gene expression and apoptotic cell counts in follicular lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.41

21 January 2018

NF-kappaB in cancer: from innocent bystander to major culprit

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.41

21 January 2018

Therapeutic anti-cancer targets upstream of the proteasome.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.41

21 January 2018

Inhibition of MEK/ERK signaling synergistically potentiates histone deacetylase inhibitor-induced growth arrest, apoptosis and acetylation of histone H3 on p21waf1 promoter in acute myelogenous leukemia cell

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.41

21 January 2018

Synergistic interactions between MEK1/2 and histone deacetylase inhibitors in BCR/ABL+ human leukemia cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.41

21 January 2018

Suberoylanilide hydroxamic acid (SAHA; vorinostat) suppresses translation of cyclin D1 in mantle cell lymphoma cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.41

21 January 2018

Proteasome inhibition to maximize the apoptotic potential of cytokine therapy for murine neuroblastoma tumors

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.41

21 January 2018

p38 MAP-kinases pathway regulation, function and role in human diseases

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.41

21 January 2018

p38alpha MAP kinase as a sensor of reactive oxygen species in tumorigenesis.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.41

21 January 2018

The hierarchical relationship between MAPK signaling and ROS generation in human leukemia cells undergoing apoptosis in response to the proteasome inhibitor Bortezomib

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.41

21 January 2018

Induction of Apoptosis in BCR/ABL+ Cells By Histone Deacetylase Inhibitors Involves Reciprocal Effects on the RAF/MEK/ERK and JNK Pathways

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.41

21 January 2018

The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.41

21 January 2018

Acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.41

7 January 2021

based on heuristic

inferred from DOI database lookup

Aggressive peripheral T-cell lymphomas (specified and unspecified types).

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.41

7 January 2021

based on heuristic

inferred from DOI database lookup

The ubiquitin proteasome pathway from bench to bedside

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.41

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment with bortezomib in a patient with heavily pretreated refractory T-cell lymphoblastic lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.41

7 January 2021

based on heuristic

inferred from DOI database lookup

Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.41

7 January 2021

based on heuristic

inferred from DOI database lookup

Signal transduction through MAP kinase cascades

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.41

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/LEU.2009.41

1 reference

Europe PubMed Central

15 September 2017

1 reference

Europe PubMed Central

15 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39873607&oldid=2091865743"